Controlled Trial of 3 4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS)

R
Robert Pascuzzi, MD

Primary Investigator

Overview

The overall purpose is to provide children access to 3,4-DAP, which is not currently approved by the FDA for use in the United States.

Description

This study is designed to provide 3,4-DAP to patients with Lambert-Eaton Myasthenic Syndrome (LEMS) in attempt to improve their quality of life.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Lambert-Eaton Myasthenic Syndrome (LEMS),Lambert-Eaton Myastenic Syndrome
  • Age: Between 4 Years - 100 Years
  • Gender: All

Inclusion Criteria
Diagnosed with Lambert-Eaton Myasthenic Syndrome
If female, have a negative pregnancy test and, if premenopausal, be willing to practice and effective form of birth control during this treatment
Exclusion Criteria
Known sensitivity to 3,4-DAP
Has a history of past or current seizures or of severe asthma
Is believed by the investigator to be unable to comply with the protocol


Additional Information:

Updated on 20 Nov 2022. Study ID: 1010002406

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center